Our results regarding the frequency of PTEN and RAS–MAPK pathway alterations suggest that this approach may have a rationale in ATRX-deficient IDH-wildtype adult gliomas and ATRX loss could be a potential marker to predict responder cases to immunotherapeutic interventions. This evidence concerns the gene ATRX and glioma.